Achilles Therapeutics PLC is a biopharmaceutical company. It is developing novel cancer immunotherapies targeting clonal neoantigens. The company has two ongoing trials, the CHIRON trial in patients with advanced non-small-cell lung cancer and the THETIS trial in patients with recurrent or metastatic melanoma.
Quote | Achilles Therapeutics plc (NASDAQ:ACHL)
Last: | $0.828899 |
---|---|
Change Percent: | 0.94% |
Open: | $0.8301 |
Close: | $0.828899 |
High: | $0.8301 |
Low: | $0.8001 |
Volume: | 30,503 |
Last Trade Date Time: | 07/26/2024 03:00:00 am |
News | Achilles Therapeutics plc (NASDAQ:ACHL)
Combines Achilles’ best-in-class AI-driven, tumor-targeting technology with Arcturus’ world-leading self-amplifying mRNA platform Combined technologies have the potential to generate potent and durable T cell responses in pre-clinical IND-enabling studies LONDON, May...
2024-05-17 17:34:04 ET More on Achilles Therapeutics Piper downgrades Achilles to neutral, cites latest data Seeking Alpha’s Quant Rating on Achilles Therapeutics Historical earnings data for Achilles Therapeutics Financial information for Achilles The...
Message Board Posts | Achilles Therapeutics plc (NASDAQ:ACHL)
Subject | By | Source | When |
---|---|---|---|
A virtual panel will take place on Thursday, | jondoeuk | investorshub | 10/07/2022 6:23:19 PM |
Link to webcast https://onlinexperiences.com/scripts/Server.nxp?LASCmd=AI%3A4%3B | jondoeuk | investorshub | 04/17/2022 10:23:10 PM |
AI model will be great for diagnosis, chronic | NY1972 | investorshub | 04/14/2022 12:17:11 AM |
The data model is not biased compared to | NY1972 | investorshub | 04/14/2022 12:11:23 AM |
I do think AI is overhyped, but not | jondoeuk | investorshub | 04/13/2022 10:38:44 PM |
News, Short Squeeze, Breakout and More Instantly...
Achilles Therapeutics plc Company Name:
ACHL Stock Symbol:
NASDAQ Market:
Achilles Therapeutics plc Website:
Combines Achilles’ best-in-class AI-driven, tumor-targeting technology with Arcturus’ world-leading self-amplifying mRNA platform Combined technologies have the potential to generate potent and durable T cell responses in pre-clinical IND-enabling studies LONDON, May...
Apartment Investment and Management Company (AIV) is expected to report for Q1 2024 Shopify Inc. Class A Subordinate (SHOP) is expected to report $0.08 for Q1 2024 Beyond Meat Inc. (BYND) is expected to report $-0.68 for Q1 2024 Instructure Holdings Inc. (INST) is expected to report $...